Prospective Evaluation of Efficacy, Safety, and Optimal Biomarker Enrichment Strategy for Nangibotide in Patients With Septic Shock
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
Lancet Respir Med 2023 May 31;[EPub Ahead of Print], B François, S Lambden, T Fivez, S Gibot, M Derive, JM Grouin, M Salcedo-Magguilli, J Lemarié, N De Schryver, V Jalkanen, T Hicheur, JJ Garaud, V Cuvier, R Ferrer, M Bestle, V Pettilä, JP Mira, C Bouisse, E Mercier, J Vermassen, V Huberlant, I Vinatier, N Anguel, M Levy, PF LaterreFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.